Q8 (R2) Step 5 Pharmaceutical Development
ICH guideline Q8 (R2) on pharmaceutical development Step 5 Transmission to CHMP December 2004 Transmission to interested parties December 2004 Deadline for comments June 2005 ... excipients, container closure systems, and manufacturing processes that are critical to product quality should be determined and control strategies justified. Critical ...
Download Q8 (R2) Step 5 Pharmaceutical Development
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Q8(R2) - ICH
database.ich.orgParent Guideline: Pharmaceutical Development Q8 Approval of the Guideline by the Steering Committee under Step 2 and release for public consultation. 18 ... excipients, container closure system, any relevant dosing device), the manufacturing process, and, if appropriate, knowledge gained from the development of similar drug ...
<1151> PHARMACEUTICAL DOSAGE FORMS - DrugFuture
www.drugfuture.comDevelopment of a compendial Excess Volume in Injections—Each container of an Injec-taxonomy and glossary for pharmaceutical dosage forms. Pharm Forum. tion is filled with a volume in slight excess of the labeled 2003;29(5):1742–1752. “size” or the volume that is to be withdrawn. The excess Official from May 1, 2012
Guideline on Inhalational medicinal products
www.ema.europa.euPharmaceutical Development). 4.2 DRUG PRODUCT PHARMACEUTICAL DEVELOPMENT Pharmaceutical development studies are conducted to establish that the dosage form, formulation, manufacturing process, container closure system, microbiological attributes and instructions for use are appropriate and result in acceptable product performance.
Annex 4 WHO guidelines for sampling of pharmaceutical ...
www.who.int— pharmaceutical products (in-process as well as before and after packaging); — primary and secondary packaging materials; and — cleaning and sanitizing agents, compressed gases and other pro-cessing agents. 1.5 Sampling facilities Sampling facilities should be designed to: — prevent contamination of the opened container, the materials and
STABILITY TESTING OF ACTIVE SUBSTANCES AND …
www.who.intand the pharmaceutical excipients, the dosage form and its composition, the manufacturing process, the nature of the container-closure system, and the properties of the packaging materials. Also, the stability of excipients that may contain or form reactive degradation products, have to be considered.